Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: Intramuscular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Polaris
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Mesothelioma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Phase 2/3 ATOMIC Study of MPM to Assess ADI-PEG 20 with PemCis v5 | P3 |
Unknown status |
Mesothelioma |
2021-09-23 |